Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
2 raisons identifiées
Praticien-chercheur
14 articles scientifiques publiés — formation continue solide
Délais de RDV courts dans la région
336.2 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
20
20 articles ont été cités au moins 20fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
1 732
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
99
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
37
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Affiliations FR : Institut Pasteur
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Splenic accumulation of intact Plasmodium ovale sensu lato-infected red blood cells in a patient presenting with splenic rupture
2026ArticlePLoS Neglected Tropical Diseases
Rabies exposure in international travellers: Experience from a single travel clinic in Paris, France, 2018–2022
2025ArticleTravel Medicine and Infectious Disease
Locally acquired malaria: a retrospective analysis of long-term surveillance data, European France, 1995 to 2022
2024ArticleEurosurveillance
Complete Genome Sequences of Monkeypox Virus from a French Clinical Sample and the Corresponding Isolated Strain, Obtained Using Nanopore Sequencing
2023ArticleMicrobiology Resource Announcements
A highly virulent variant of HIV-1 circulating in the Netherlands
2022ArticleScience
Systematic Booster after Rabies Pre-Exposure Prophylaxis to Alleviate Rabies Antibody Monitoring in Individuals at Risk of Occupational Exposure
2021ArticleVaccines
Immune response to rabies post-exposure prophylaxis in patients with non-HIV secondary immunodeficiencies
2020ArticleVaccine
Rifampin-moxifloxacin-metronidazole combination therapy for severe Hurley Stage 1 Hidradenitis Suppurativa: prospective short-term trial and one-year follow-up in 28 consecutive patients
2020ArticleJournal of The American Academy of Dermatology
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
CDS DE L INSTITUT PASTEUR
211 R DE VAUGIRARD, 75724 PARIS CEDEX 15
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Dermatology (Basel, Switzerland) · 2011
<i>Background:</i> Antibiotics have been shown to improve hidradenitis suppurativa (HS) patients but complete remission is rare using these treatments. <i>Objective:</i> To assess the efficacy and safety of a combination of oral rifampin, moxifloxacin and metronidazole in long-lasting refractory HS. <i>Methods:</i> We retrospectively studied 28 consecutive HS patients including 6, 10 and 12 Hurley stage 1, 2 and 3 patients, respectively. Complete remission, defined as a clearance of all inflammatory lesions including hypertrophic scars, was the main outcome criterion of the study. <i>Results:</i> Complete remission was obtained in 16 patients, including 6/6, 8/10 and 2/12 patients with Hurley stage 1, 2 and 3, respectively (p = 0.0004). The median duration of treatment to obtain complete remission was 2.4 (range 0.9–6.5) and 3.8 months (range 1.6–7.4) in stage 1 and 2 patients, respectively, and 6.2 and 12 months in the 2 stage 3 patients. Main adverse events of the treatments were gastrointestinal disorders (64% of patients) and vaginal candidiasis (35% of females). Reversible tendinopathy and hepatitis occurred in 4 and 1 patient, respectively. <i>Conclusions:</i> Complete remission of refractory HS can be obtained using broad-spectrum antibiotics and Hurley staging is a prognostic factor of response to the treatment.
Arthritis care & research · 2013
ObjectiveTo assess the safety and immunogenicity of live attenuated yellow fever (YF) 17D vaccine in adults receiving systemic corticosteroid therapy.MethodsAll adult travelers on systemic corticosteroid therapy who had received the YF17D vaccine in 24 French vaccination centers were prospectively enrolled and matched with healthy controls (1:2) on age and history of YF17D immunization. Safety was assessed in a self‐administered standardized questionnaire within 10 days after immunization. YF‐specific neutralizing antibody titers were measured 6 months after vaccination in patients receiving corticosteroids.ResultsBetween July 2008 and February 2011, 102 vaccine recipients completed the safety study (34 receiving corticosteroids and 68 controls). The median age was 54.9 years (interquartile range [IQR] 45.1–60.3 years) and 45 participants had a history of previous YF17D immunization. The median time receiving corticosteroid therapy was 10 months (IQR 1–67 months) and the prednisone or equivalent dosage was 7 mg/day (IQR 5–20). Main indications were autoimmune diseases (n = 14), rheumatoid arthritis (n = 9), and upper respiratory tract infections (n = 8). No serious adverse event was reported; however, patients receiving corticosteroids reported more frequent moderate/severe local reactions than controls (12% and 2%, respectively; relative risk 8.0, 95% confidence interval 1.4–45.9). All subjects receiving corticosteroids who were tested (n = 20) had neutralizing antibody titers >10 after vaccination.ConclusionAfter YF17D immunization, moderate/severe local reactions may be more frequent in patients receiving systemic corticosteroid therapy. Immunogenicity seems satisfactory. Large‐scale studies are needed to confirm these results.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2013
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
PLoS neglected tropical diseases · 2026 · Journal Article
Benabdelmoumen G, Itani O, Joste V, Houzé S, et al.
The American journal of medicine · 2025 · Journal Article
Itani O, Kuhmel L, Etienne N, Consigny PH
Journal of travel medicine · 2025 · Journal Article
Taieb F, Baidaliuk A, Durand A, Prot BSc M, et al.
Journal of travel medicine · 2024 · Journal Article
Itani O, Caumes E, Consigny PH
Medecine tropicale et sante internationale · 2024 · Journal Article
Consigny PH
The Journal of infectious diseases · 2018 · Letter
Sicre de Fontbrune F, Consigny PH
Cardiovascular and interventional radiology · 2014 · Journal Article
Consigny PM, Davalian D, Donn R, Hu J, et al.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2013 · Journal Article
Lortholary O, Charlier C, Lebeaux D, Lecuit M, et al.
Journal of travel medicine · 2012 · Journal Article
Socolovschi C, Honnorat E, Consigny PH, Dougados J, et al.
Dermatology (Basel, Switzerland) · 2011 · Journal Article
Join-Lambert O, Coignard H, Jais JP, Guet-Revillet H, et al.
Journal of travel medicine · 2009 · Case Reports
Consigny PH, Schuett I, Fraitag S, Rolain JM, et al.
Journal of travel medicine · 2007 · Case Reports
Pérignon A, Pelicot M, Consigny PH
Arthritis care & research · 2013 · Journal Article
Kernéis S, Launay O, Ancelle T, Iordache L, et al.
Clinical and experimental immunology · 2002 · Journal Article
Consigny PH, Cauquelin B, Agnamey P, Comby E, et al.
Arthritis care & research · 2013 · Journal Article
Kernéis S, Launay O, Ancelle T, Iordache L, et al.
Arthritis care & research · 2013 · Journal Article
Kernéis S, Launay O, Ancelle T, Iordache L, et al.
✨ Profil synthétique
IA · 19/05/2026Le Dr Paul Henri Consigny est un rhumatologue salarié à Paris, avec une production scientifique significative dans le domaine des maladies infectieuses et de la santé liée aux voyages. Son h-index de 20 et ses 99 publications reflètent son engagement dans la recherche. Ses travaux portent notamment sur l'épidémiologie, la corticothérapie et la pharmacovigilance.
Expertises présumées
Synthèse automatique à partir des sources publiques (HAL, OpenAlex, theses.fr, ClinicalTrials.gov, FAI²R, ANS). Pas une évaluation clinique. Le médecin peut corriger via son compte.